Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice

J Biochem Mol Toxicol. 2017 Apr;31(4). doi: 10.1002/jbt.21877. Epub 2016 Nov 30.

Abstract

Overdose of acetaminophen (APAP) is often associated with hepatotoxicity. Carfilzomib (CFZ) shows multiple pharmacological activities including anti-inflammatory potential. Therefore, this study was undertaken to evaluate the possible therapeutic effects of CFZ against APAP-induced hepatotoxicity. Hepatotoxicity was induced by administration of APAP (350 mg/kg, intraperitoneal). Mice were given CFZ (0.125, 0.25, or 0.5 mg/kg, intraperitoneal) 1.5 h after APAP administration. Animals were sacrificed on 6 h and blood and liver tissue samples were collected for analysis. In CFZ-post-treated group, there was significant and dose-dependent decrease in serum alanine aminotransferase levels. The level of tumor necrosis factor-α (TNF-α), reactive oxygen species, and NO decreased, whereas glutathione increased significantly by CFZ post-treatment. Upregulated mRNA expression of COX-II and iNOS were significantly downregulated by CFZ post-treatment. CFZ may exert its hepatoprotective action by alleviating inflammatory, oxidative, and nitrosative stress via inhibition of TNF-α, COX-II, and iNOS.

Keywords: COX-II and iNOS; TNF-α; acetaminophen; carfilzomib; hepatotoxicity; oxidative and nitrosative stress.

MeSH terms

  • Acetaminophen / administration & dosage
  • Acetaminophen / adverse effects
  • Acetaminophen / toxicity*
  • Animals
  • Cyclooxygenase 2 / drug effects
  • Cyclooxygenase 2 / genetics
  • Gene Expression Regulation
  • Glutathione
  • Inflammation / drug therapy
  • Injections, Intraperitoneal
  • Liver / drug effects*
  • Liver / metabolism
  • Male
  • Mice
  • Nitric Oxide Synthase Type II / drug effects
  • Nitric Oxide Synthase Type II / genetics
  • Oligopeptides / administration & dosage
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use*
  • Oxidative Stress / drug effects
  • Proteasome Inhibitors / pharmacology
  • Proteasome Inhibitors / therapeutic use*
  • Reactive Oxygen Species

Substances

  • Oligopeptides
  • Proteasome Inhibitors
  • Reactive Oxygen Species
  • Acetaminophen
  • carfilzomib
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2
  • Glutathione